GGrantIndex
← Search

ACTG 388: EFZ OR NFV IN COMBINATION W/ FDC 3TC/ZDV &IDV

$0M01FY2000RRNIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications & trials

Abstract

To evaluate and compare the ability of elavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or nelfinavir (NFV) a protease inhibitor, in combination with fixed dose combination (FDC) 3TC/ZDV plus indinavir (IDV) versus FDC 3TC/ZDV plus IDV, to achieve suppression of plasma HIV RNA to below the limit of detection (<200 copies/mL HIV RNA.)

View original record on NIH RePORTER →